Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 11:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 2,796 matching trials from the live ClinicalTrials.gov search.
Conditions
Neurodegeneration With Brain Iron Accumulation (NBIA)
Interventions
Not listed
Lead sponsor
Susan J. Hayflick
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Cardiovascular Diseases
Interventions
d-Coaching
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Francisco, California • Decatur, Georgia
Conditions
HIV Infections
Interventions
ARV regimen chosen by treating physician
Drug
Lead sponsor
Kristine Patterson, MD
Other
Eligibility
19 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Breast Cancer, Obesity, Weight Changes
Interventions
behavioral dietary intervention, Exercise intervention
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Completed Early Phase 1 Interventional Accepts healthy volunteers

Soy Supplementation and Gestational Diabetes

NCT02806739
Conditions
Gestational Diabetes
Interventions
Soy Group (Soy Protein + Isoflavones), Control Group (Minimize Soy Intake)
Dietary Supplement
Lead sponsor
University of Massachusetts, Boston
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions
Heart Math Biofeedback Breathing Practices, Nutrition Counseling combined with Exercise Counseling
Behavioral
Lead sponsor
Hoskinson Health and Wellness Clinic
Industry
Eligibility
7 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gillette, Wyoming
Completed Phase 4 Interventional Accepts healthy volunteers

IV vs Oral Acetaminophen in Spine Fusion Perioperative Care

NCT03020875
Conditions
Multimodal Analgesic Approach
Interventions
Ofirmev, Per Os Acetaminophen
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Combined Behavioral Interventions on Cognitive Outcomes in MCI

NCT02864069
Conditions
Mild Cognitive Impairment
Interventions
Walking Intervention, Cognitive Training Intervention, Combined Intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
60 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Conditions
Lymphoma, Follicular
Interventions
Ofatumumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Prednisone or equivalent
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Completed Phase 3 Interventional Results available

Safety and Efficacy of Albiglutide in Type 2 Diabetes

NCT00849056
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
310
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 250 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Rapid UTI Diagnostics in Lower Urinary Tract Dysfunction Among Catheter Users

NCT07784829
Conditions
Neurogenic Bladder Disorder, Lower Urinary Tract Disorder, Urinary Tract Infection (Diagnosis)
Interventions
urine Resazurin Reduction Ratio, USQNB
Diagnostic Test · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Carfilzomib, dexamethasone, Daratumumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Conditions
Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
Interventions
PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI, FOLFOX, Gemcitabine, Mirvetuximab Soravtansine, Trastuzumab Deruxtecan
Biological · Drug
Lead sponsor
Pheast Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
Conditions
Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
35
States / cities
Chandler, Arizona • Anaheim, California • San Diego, California + 28 more
Conditions
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions
Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
1,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
191
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Advanced Tumors
Interventions
CPI-100, Capecitabine
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • San Antonio, Texas
Conditions
Mesothelioma, Peritoneal Mesothelioma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Latanoprost, Arm 2, Latanoprost SR insert
Drug
Lead sponsor
Daniel Moore
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Conditions
Hypertension, Diabetes Mellitus
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Healthy, Hepatitis C, Chronic
Interventions
TG-2349, placebo
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cypress, California
Conditions
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida